The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN
1. REGN faces a class action lawsuit alleging misleading sales practices.
2. Claims include undisclosed credit card fee payments influencing Eylea's sales prices.
3. Allegations suggest violations of the False Claims Act regarding sales reporting.
4. Class period spans November 2, 2023, to October 30, 2024.
5. Shareholders can register for participation before the March 10, 2025 deadline.
The allegations of misleading practices could lead to regulatory scrutiny and lower investor confidence, as seen in past cases like Theranos, which severely impacted stock values.
How important is it?
The legal ramifications could have significant financial implications for REGN, affecting shareholder trust and stock valuation.
Why Short Term?
The lawsuit could cause immediate concerns among investors, similar to prior class actions affecting short-term stock performance.
NEW YORK, Jan. 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN).
Shareholders who purchased shares of REGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that:
Regeneron paid credit card fees to distributors on the condition that distributors did not charge, one of the Company's primary products, Eylea customers more to use a credit card;
these payments subsidized the prices that customers paid when using credit cards to purchase Eylea;
as a result, Regeneron offered a price concession that lowered Eylea's selling price;
because retina practices were sensitive to higher prices when using credit cards to purchase anti-VEGF medications, Regeneron's price concessions provided a competitive advantage;
as a result of the foregoing, Regeneron misleadingly boosted reported Eylea sales;
by failing to report its payment of credit card fees as price concessions, Regeneron overstated the ASP reported to federal agencies, thereby violating the False Claims Act;
as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Once you register as a shareholder who purchased shares of REGN during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is March 10, 2025. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM?
The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: info@grosslawfirm.com
Phone: (646) 453-8903
